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Abstract: The intestinal microbiota and gut immune system must constantly communicate 
to maintain a balance between tolerance and activation: on the one hand, our immune 
system should protect us from pathogenic microbes and on the other hand, most of the 
millions of microbes in and on our body are innocuous symbionts and some can even be 
beneficial. Since there is such a close interaction between the immune system and the 
intestinal microbiota, it is not surprising that some lymphomas such as mucosal-associated 
lymphoid tissue (MALT) lymphoma have been shown to be caused by the presence of 
certain bacteria. Animal models played an important role in establishing causation and 
mechanism of bacteria-induced MALT lymphoma. In this review we discuss different 
ways that animal models have been applied to establish a link between the gut microbiota 
and lymphoma and how animal models have helped to elucidate mechanisms of 
microbiota-induced lymphoma. While there are not a plethora of studies demonstrating a 
connection between microbiota and lymphoma development, we believe that animal 
models are a system which can be exploited in the future to enhance our understanding of 
causation and improve prognosis and treatment of lymphoma. 
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1. Introduction 
Lymphocytes play a key role in responding to microbial colonization by initiating an immune 
response leading to tolerance or activation. The majority of immunologically active cells belong to the 
mucosal-associated immune system and are constantly receiving signals from dendritic cells or other 
APCs which are sampling the intestines. Dysregulation can lead to inflammation-related diseases such 
as colitis and cancer, as reviewed in this issue. Tissues closely associated with bacterial exposure have 
been most easily identified as being affected by microbes such as colon cancer and gastric cancers [1] 
and in current issue) however intestinal health can alter extra-gastrointestinal tissues, having a 
systemic effect [2,3]. Animal models have played an essential role in understanding the importance of 
the gut microbiome in immune development and composition [4]. Animal models have also played a 
key role in solidifying the relationship between the microbiome and health and disease [5]. Techniques 
to manipulate animal gut composition have been studied and refined for over 50 years and continue to 
play an important role in clarifying this symbiotic and sometimes pathogenic relationship [6].  
2. Microbiota and Lymphoma in Animal Models 
There are two major ways that animal models have an advantage in studying the relationship 
between gut microbes and cancer. First, the mouse gut microbiome can be altered to be germ free, 
contain specific species of bacteria (gnotobiotic), or to have what is commonly called conventional 
microbiota, which is considered “normal” and generally unmonitored in genetically similar animals. 
Changing the microbiome allows us to study cause and effect relationship between the bacteria and 
body. Germfree animals have demonstrated the role of microbiota in inflammation, metabolism, and 
obesity [5,7,8]. Gnotobiotic models have helped to determine both causative species and mechanisms 
of colorectal cancer [9,10]. Second, animal models have been used to determine how genes may affect 
or be affected by different bacteria. These models can help us determine genetic susceptibility or 
resistance to different diseases depending on microbial exposure. For example polymorphisms in 
Dectin1 can influence susceptibility to colitis [11]. Alternatively, genetic models can help us determine 
which genes or pathways may be important in disease development or protection [12]. For example, 
Rag2-/- mice can develop H. hepaticus-induced cancer, however immune competent mice are 
protected due to a regulatory response leading to decreased inflammation [13]. Combining both  
a defined gut microbiota and genetic models can also give us important insights into mechanisms of 
gut-microbe interactions.  
2.1. Historical Data Indicating That Gut Microbes May Affect Mouse Phenotypes Such as Cancer  
and Lifespan  
While inbred mouse strains have helped to decrease variability among and within experiments, over 
time even these carefully maintained strains may acquire differences. Changes in phenotypes of research 
animals have been noted as early as 1966 in various fields from radiation to toxicology [14–18]. Internal 
factors such as genetic drift or spontaneous mutations can play a role in varying phenotypes of 
research animals [19,20]. Many environmental factors have also been postulated to contribute to 
changes in rodents including housing conditions, diet, and sterility [15,17,21]. 
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Significant changes in lifespan or tumor incidence may have important consequences on 
experimental results. For example, over an 11 year period, percent survival of male F344 rats at 106 
weeks decreased from 85.3% in experiments starting in 1971 to 62.5% in experiments starting in 
1980–1981 [16]. In addition, leukemia incidence increased from 9.4% to 20.1% in male rats in 
experiments starting in 1972–1973 and 1980–1981, respectively [16]. Experiments using 3 Gy X-rays 
to induce myeloid leukemia show that 32.3% of mice developed the disease in 1956 while only 12.8% 
developed myeloid leukemia in 1964 [17]. While different environmental factors have been attributed 
to these changes, it is well known that animal husbandry protocols have also become more stringent, 
affecting animal microbial composition and health [22]. More recently, our lab has shown that in 
different vivariums, with different specific pathogen free (SPF) conditions, isogenic mice have altered 
lifespans and lymphoma latency periods [18,23]. This correlates to distinct microbiome profiles as 
determined by 16S rRNA lengths. Therefore it is likely that the microbiome has at least a partial 
influence on animal health, including carcinogenesis. 
2.2. Animal Models of Mucosal-Associated Lymphoid Tissue (MALT) Lymphoma 
Mucosal-associated lymphoid tissue (MALT) lymphomas are thought to originate in the marginal 
zone and are strongly associated with the presence of Helicobacter [24,25]. Approximately 90% of 
MALT lymphomas are associated with Helicobacter infection [26]. Elimination of Helicobacter leads 
to complete remission in approximately 80% of all cases [27]. While the association of H. pylori and 
MALT lymphoma was discovered in humans, the causative effect of Helicobacter in MALT 
lymphoma development, according to the Koch’s Postulate, was demonstrated in animal models.  
A model of bacteria-induced MALT was first shown in mice by infection with H. felis, a close relative 
to H. pylori. Twenty two weeks post-infection, 25% of infected mice had lymphoepithelial lesions 
while none of the non-infected animals did [28]. An H. pylori infection was first established in gerbils 
and showed an increase in gastritis and intestinal metaplasia [29]. Since then, H. pylori infections have 
been established in mouse models and have been used to examine mechanism by assessing 
transcription profiling [30] and disease progression and regression [31].  
H. helmanii, found in both human and mice, also leads to MALT lymphoma which is preceded by 
inflammation and high endothelial venule-like vesicles, which are associated with lymphocyte 
recruitment and present in other chronic inflammatory conditions such as rheumatoid arthritis, and 
colitis [32]. The animal models of H. helmanii-induced lymphoma, however, seem to have varying 
results and may also involve host and bacterial factors [33]. The use of better defined bacteria, 
however, may improve consistency and development of MALT lymphoma for future studies [34]. 
Other bacteria such as Campylobacter jejuni, Borrelia bergdorferi, and Chlamidia psitacci may 
also play a role in lymphoma development, however these associations have only been shown in 
humans thus far [35]. Streptococcus bovis has been associated with hematopoietic malignancy in 
humans [36]. Therefore, animal models may provide valuable insight into microbe-associated 
lymphoma etiology, progression, and treatment. 
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2.3. Animal Models of Lymphoma and Effects of the Microbiome 
Animal models of cancer can also be useful in demonstrating a link between the microbiome and 
carcinogenesis. Cancer is a disease that is generally thought to occur in a multi-step process beginning 
with initiation, promotion, and finally progression. As the disease progresses, cells acquire “hallmarks 
of cancer” which include sustained proliferation, resistance to cell death, and metastasis [37]. Using 
animal cancer models such as p53-deficient mice, allows researchers to bypass some steps required for 
overt cancer saving time and animal numbers. ApcMin/+ mice, which spontaneously develop intestinal 
polyps, have been used to demonstrate that infection with Citrobacter rodentium or enterotoxin-producing 
Bacterioides fragilis can promote colon cancer [38,39]. A chemically induced model of liver cancer 
also showed that Helicobacter hepaticus infection promotes liver tumorigenesis [40]. 
Our lab has shown that mice deficient in the Ataxia telangiectasia mutated gene (Atm-/- mice), 
which display genetic instability and spontaneously develop a high incidence of thymic  
lymphoma [41,42], are sensitive to changes in microbial content [23]. We found that as Atm-/- mice 
moved to more sterile conditions, they began to live longer and have a decreased lymphoma 
penetrance [18,23]. Conversely, when they were moved to standard SPF conditions, their lifespan and 
lymphoma latency decreased. To test the effects of the gut microbiota more directly, we rederived 
mice into a restricted microbiota facility [43] and “conventionalized” mice by inoculating them with 
fecal samples from conventional SPF mice. Again, the “conventionalized” mice had shorter lifespans 
than the mice with a restricted flora [23]. These results indicated that microbes in the restricted, sterile 
facility had a protective effect in Atm-/- mice and/or the conventional microbiota had a more 
pathogenic effect. One microbe that was highly enriched in the restricted microbiome was 
Lactobacillus johnsonii. Inoculation with L. johnsonii in Atm-/- mice decreased measures of DNA 
damage, oxidative stress, and inflammation [23]. These results indicate that the gut microbiota can 
impact lymphomagenesis in Atm-/- mice. Other lymphoma or cancer models may also contribute to the 
growing body of evidence linking the microbiome to carcinogenesis. 
3. Mechanism of Microbiota-Induced Lymphomagenesis as Evidenced in Animal Models 
While there is not a plethora of animal models linking the microbiome to lymphoma development, 
there is a large amount of data indicating plausible mechanisms of microbiota-induced lymphomagenesis 
in animal models. Since the intestinal microbiota has been shown to influence the immune system 
directly and indirectly ([44,45] and in the current issue), there are several ways that the intestinal 
microbiota may affect lymphomagenesis in mice. Many of these mechanisms have been identified and 
shown in animal models. 
3.1. Microbiota Can Directly Initiate Lymphomagenesis 
Species of gut bacteria may directly cause the promotion or neutralization of mutagens and 
oxidative stress [46–54] leading to DNA damage and subsequent cancer or protection [55] From here 
on the reference No need to be shifted for one number see attached original. Faecal water samples 
from mice treated with pre- and probiotics showed different degrees of genotoxicity which correlated 
with tumorigenesis [55]. Bacteria can also directly interact with immune cells causing oxidative  
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bursts [56] or necrosis [56], and with epithelial cells causing increased production of reactive oxygen 
species and inhibition of NF-κB [57]. Oxidative stress can then lead to DNA damage and 
carcinogenesis [58–60]. H. pylori and C. jejuni have both been shown to increase oxidative  
stress [53,54]. Finally, bacteria can act as an antigen and stimulate chronic proliferation of immune 
cells. H. pylori is thought to cause lymphoma because of constant stimulation of antigen presentation 
leading to B cell expansion [31,61]. In humans, this is evident in the overrepresentation of certain V 
genes [35,62]. While the lymphocytes and microbes are generally separated by the epithelial barrier, 
bacteria, antigens, or metabolites cross the mucosal barrier through dendritic cells or M cells which are 
constantly sampling the lumen [63]. In addition to causing damage, bacteria can also help to neutralize 
mutagens and oxidative stress ([64], reviewed in [65]). The mutagens MNNG and DMH have been 
shown to be neutralized in rat colons by lactic acid bacteria. 
3.2. Microbiota Can Alter Immune Parameters to Affect Lymphomagenesis 
Species, or populations of gut bacteria may cause a change in immune response or immune 
parameters and affect lymphocytes. Intestinal immune cells are constantly sampling luminal content 
and deciding whether to elicit or suppress an immune response [44]. Animal studies have shown that 
both single species of bacteria as well as different bacterial compositions can have large impacts on 
immune parameters. For example, studies using germ-free mice established that intestinal microbiota 
are essential for normal immune system development [66–68]. Since lymphoma itself is a shift in 
immune cell types, it is not surprising that microbes may influence lymphomagenesis. 
Several animal studies have shown that either a mixture of bacteria or single species may 
significantly affect immune cell population and activity [43,69–73]. For example, inoculation with 
segmented filamentous bacteria caused a change in T cell activity eliciting a range of responses 
including increases in IL-10, IL-17, and IFN-γ [72]. In addition, inoculation of Sphingomonas 
yanoikuyae caused a systemic change in immune cell populations [43]. Bacterioides fragilis can 
induce a Th17 response in mice which was then shown to be required for tumorigenesis [39]. Bacteria 
can also directly alter inflammation-related pathways. Inoculation with common human commensal 
bacterium B. thetaiotaomicron, B. longum, or both resulted in an increase in TNF-α- and IFN-γ-associated 
pathways [74]. These studies indicate that gut microbes can affect the immune system which may 
impact lymphoma development. 
Alternatively, distinct compositions of intestinal microbiota can differentially alter immune 
parameters [43,69,70] which may protect mice against cancerous cells. Mice with a restricted 
microbiota have increased cytotoxic T cells which leads to decreased levels of marginal zone B  
cells [69], invariant NKT (iNKT) cells [70], and plasmacytic dendritic cells compared to mice with 
conventional flora [43]. Moreover, Wei et al. suggest that the activity of adoptively transferred 
cytotoxic CD8+ T cells can be increased if recipient mice are inoculated with donor microbial  
antigens [69]. It has also been shown that germ-free colorectal cancer rat models mount different 
responses to cancer induction compared to conventional mice including increased B cells, NK cells 
and cytotoxic T lymphocytes [75].  
Conversely, some bacteria and bacterial products may have a beneficial effect. For example, lactic 
acid bacteria and specific recognition of Lactobacilli may protect against carcinogenesis [76,77]. 
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Lactobacillus johnsonii in rat intestines has been shown to have a positive effect on oxidative stress 
and inflammation and prolongs the development of diabetes [78,79]. Lactic acid bacteria can also 
modify the immune system to prevent cancer in mouse tumor models ([80–82] (reviewed in [65,83]). 
In addition, butyrate, a short-chain fatty acid produced by bacterial fermentation of fiber on Treg cell 
specification and expansion [84,85]. 
Whether microbes influence immune cells directly, indirectly, or a combination of both, increased 
lymphocyte proliferation can lead to a higher chance of aberrant DNA replication [86,87], particularly 
in some B lymphocytes which are innately vulnerable to genetic instability [88,89] and activation [90]. 
Oxidative stress caused by intestinal microbiota either directly [91] or indirectly through the immune 
system [92], can also affect carcinogenesis. Therefore, the microbiota can affect several pathways 
associated with lymphomagenesis [93,94]. 
4. Conclusions 
While there is evidence that the microbiome affects lymphomagenesis, particularly MALT 
lymphomas, there is a wide gap of knowledge to which animal models could provide valuable 
answers. Namely, which bacteria or bacterial products can cause, protect against, or increase risk of 
lymphoma development? With the exception of breast cancer, liver cancer, and lymphoma, systemic 
effects of intestinal bacteria on cancer have not been studied. Lymphomas are of particular interest 
because they circulate through the gastro-intestinal system as well as the rest of the body. The fact that 
more lymphomas are becoming associated with bacterial infections [95–97] and that antibiotic therapy 
can be effective [95,97] underscores the need for more studies involving microbes and lymphoma. 
There is overwhelming evidence that some intestinal bacteria are health beneficial like the 
Lactobacilli whereas some others are health detrimental like some of the Helicobacteraceae. It will be 
very important to determine the roles as health beneficial and detrimental of most intestinal bacteria and 
whether there are synergisms or antagonisms between them. Then one can design certain probiotics 
containing the health beneficial and certain antibiotics against the health detrimental bacteria. 
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